log-rank test – Communicable Diseases Research

COVID-19 and the injured patient: A multicenter review

Research article

Published on 2022-12-012022-10-05
Journal: The Journal of surgical research [Category] 바이오마커,

Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department

Article

Published on 2022-09-012022-11-15
Journal: Internal and Emergency Medicine [Category] 바이오마커,

Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study

코로나바이러스 질병 2019(COVID-19) 환자 치료를 위한 렘데시비르 플러스 덱사메타손 대 덱사메타손 단독 요법: 보충 O2 요법이 필요한 환자: 전향적 통제된 비무작위 연구

Controlled Clinical Trial

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제,

[키워드] 30-Day mortality Antiviral baseline calculated clinical outcomes cohorts Combination Controlled coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP D-dimer Dexamethasone drug effective Endpoint enrolled evaluate evaluated faster fibrinogen FiO2 group groups Hospitalization IMPROVE independent Inflammatory inflammatory markers Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory characteristics log-rank test median Mortality neutrophil neutrophil/lymphocyte ratio no differences occurred primary endpoint primary endpoints Prospective reducing mortality reduction in reduction in mortality Remdesivir Respiratory failure Respiratory function Sample size SARS-CoV-2 clearance secondary Secondary endpoints shown significant difference significant differences survival the log-rank test therapy treat Treatment viral clearance were used
[DOI] 10.1093/cid/ciac014 PMC 바로가기 [Article Type] Controlled Clinical Trial

Predictive value of neutrophil-to-lymphocyte ratio for the fatality of COVID-19 patients complicated with cardiovascular diseases and/or risk factors

Research

Published on 2022-08-102022-10-05
Journal: Scientific Reports [Category] 바이오마커, 임상, 치료법, 치료제,

[키워드] Analysis baseline cardiovascular disease characteristic Characteristics characterized clinical implication clinical parameter Cluster conducted COVID-19 patient COVID-19 patients Cox proportional hazard cumulative mortality diagnostic disease severity fatality Follow-up groups high mortality hospitalized COVID-19 patient implication In-hospital death increase in independent Kaplan–Meier method log-rank test Mortality Neutrophil-to-lymphocyte ratio NLR overlap Patient patients with COVID-19 poor prognosis Predictive value previous study prognostic Prognostic factor quartile Regression model reported risk factor ROC selected significant difference significantly increased survival survival analysis the timing two-dimensional was tested
[DOI] 10.1038/s41598-022-17567-4 [Article Type] Research

Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus

백만 건 이상의 COVID-19 백신 접종의 실제 증거는 수두 대상포진 바이러스의 재활성화와 일치합니다

Article

Published on 2022-08-012022-09-11
Journal: Journal of the European Academy of Dermatology and [Category] Coronavirus, MERS, 대상포진, 두창, 수두, 진단, 치료기술, 홍역,

[키워드] 95% CI 95% confidence interval accounted Adverse drug reaction adverse event Adverse reaction age and gender assumed calculated cause clinic Cohort COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines database detectable diagnosed drug reaction eruption Evidence Frequency herpes zoster humans Hypothesis incidence individual Infection initial large cohort log-rank test mitigate molecular basis Odds ratio Pathogenesis Patient patients Reactivation real-world data retrieved risk risk ratio shingle shingles significantly higher statistically subject synonym T-cell-mediated immunity vaccination Vaccine Vaccines Varicella-Zoster Virus virus with infections
[DOI] 10.1111/jdv.18184 PMC 바로가기 [Article Type] Article

D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia

Research Article

Published on 2022-02-282022-10-29
Journal: Oxidative Medicine and Cellular Longevity [Category] COVID-19, COVID19(2023년), MERS, SARS,

[키워드] age Belgrade Can center clinical Clinical outcome COVID-19 outbreak COVID-19 patients criteria Critically ill Critically ill patient CRP cutoff value D-dimer diagnosis of COVID-19 discharged disease effective female FEU for inclusion Health care hospital Hospitalization ICU identify IL-6 IMPROVE in-hospital death prediction in-hospital mortality intensive care unit Level log-rank test male management median age Mortality Patient patients died patients treated PCT predict predictor procalcitonin recognize Result retrospective cohort study ROC Curve statistically significant survival the Kaplan-Meier method Treatment was determined were used with COVID-19
[DOI] 10.1155/2022/8997709 PMC 바로가기 [Article Type] Research Article

Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients

Research Article

Published on 2022-02-232022-10-28
Journal: PLoS ONE [Category] COVID-19, COVID19(2023년), MERS, SARS,

[키워드] 48 hour all-cause mortality all-cause mortality rate analyzed Clinical improvement Cohort cohorts combination therapy Comparative conducted Corticosteroid COVID COVID-19 COVID-19 patient COVID-19 patients Cox proportional hazard Critically ill Efficacy groups hazard Hospitalized IMPROVE in-hospital mortality incidence Infection infections Kaplan-Meier Length log-rank test LOS monotherapy MRSA network Observational cohort study on mechanical ventilation outcome oxygen support Patient Primary outcome propensity score matching Pseudomona PSM Ratio RDV reduce reducing Remdesivir requiring supplemental oxygen secondary significant decrease Staphylococcus aureus stratified survival therapy Ventilated ventilatory support with COVID-19
[DOI] 10.1371/journal.pone.0264301 PMC 바로가기 [Article Type] Research Article

Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial

COVID-19 폐렴 및 전신 염증의 특징으로 입원한 환자에서 Sarilumab의 조기 사용: SARICOR 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-02-152022-09-12
Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 임상, 진단,

[키워드] acute respiratory distress added ARDS clinical comparison control group Controlled clinical trial Corticosteroids death early treatment Efficacy and safety feature FIVE hazard ratio HFNO Hospitalized hospitalized patient IL-6 blockade IMV interleukin 6 Invasive mechanical ventilation log-rank test mechanical ventilation nasal oxygenation NIMV Non-invasive Open-label outcomes participant Patient Pneumonia Primary outcome randomization Randomized receive Registered Safe sarilumab SARS-CoV-2 SARS-CoV-2. COVID-19 single dose Standard of care subcutaneous dose supplemental oxygen syndrome systemic systemic inflammation Tocilizumab with COVID-19
[DOI] 10.1128/AAC.02107-21 PMC 바로가기 [Article Type] Randomized Controlled Trial

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19

중증 COVID-19 환자의 회복기 혈장 치료를 위한 2상 단일 센터 공개 라벨 무작위 대조 시험

Clinical Trial

Published on 2022-01-192022-09-12
Journal: Nature Communications [Category] SARS, 임상, 진단, 치료기술, 치료법,

[키워드] 95% confidence interval adverse effect Adverse reaction all-cause mortality ARDS benefit characterized clinical clinical benefit clinical trial clinical trials Controlled trial convalescent plasma Convalescent plasma therapy COVID-19 disease cytokine Cytokines enrolment Evidence FiO2 General Hospital hazard hyper-inflammation immunization immunological inclusion criteria India Infectious disease Infectious diseases Intervention Kolkata log-rank log-rank test Mantel-Haenszel mechanical ventilation Mild Mild ARDS moderate moderate ARDS Mortality neutralizing antibody not affect not significantly different on mechanical ventilation open label outcome Outcomes research p value PaO2 paO2/fiO2 passive immunization Patient patients patients hospitalized PCR Phase 2 plasma plasma therapy prespecified outcomes Primary outcome Primary outcomes proteome randomised randomised controlled trial Randomized Ratio recruited Registered registry reported response to therapy secondary outcome Secondary outcomes severe COVID-19 severe COVID-19 disease severe COVID-19 patient severe COVID-19 patients single center Standard of care systemic hyper-inflammation the systemic hyper-inflammation therapy treat Treatment treatment arm Trial viral infection Viral RNA was done
[DOI] 10.1038/s41467-022-28064-7 PMC 바로가기 [Article Type] Clinical Trial

First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy

중증 폐렴으로 입원한 COVID-19 환자의 1차 및 2차 유행: 이탈리아의 한 대학병원의 1년 대유행 동안 28일 사망률 비교

Observational Study

Published on 2022-01-032022-09-11
Journal: BMJ Open [Category] SARS, 변종, 임상,

[키워드] 28-day mortality 95% CI 95% CIs age all-cause mortality Analysis circulating cohort study Comorbidity contributed COVID-19 COVID-19 pneumonia Cox regression model death duration of symptom epidemic wave Epidemiology European Factor First wave hospital Hospital admission hospitalised patient Hospitalised patients identify IQR Italy Kaplan-Meier Kaplan-Meier curve log-rank test median median age Modena mortality rate multivariable Cox regression multivariable Cox regression model Observational cohort study pandemic PaO Patient predictor reduced respiratory infections risk of death second wave sensitivity analysis Severe COVID-19 pneumonia severe pneumonia shown Standard suggested survival survival analysis university university hospital variant was performed Wave Waves were used with COVID-19 women
[DOI] 10.1136/bmjopen-2021-054069 PMC 바로가기 [Article Type] Observational Study